AidsmapTwo studies of switching from oral to injectable PrEP (regular medication to prevent HIV infection) in upper middle-income countries have found that the price of injectable long-acting cabotegravir (CAB-LA) would have to drop to considerably less than $100 a year for it to be cost-effective in terms of stopping more infections, and saving more money in future healthcare costs, than using oral tenofovir/emtricitabine (TDF/FTC) pills. The studies were presented at the 12th International AIDS Society Conference on HIV Science (IAS 2023) in Brisbane, Australia.
Read the full story at Aidsmap.
Source : Aidsmap
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.